An observational study in Lymphoma, Mantle-Cell, sponsored by Xian-Janssen Pharmaceutical Ltd.. Completed at 9 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-11-06.
Sponsored by Xian-Janssen Pharmaceutical Ltd. (part of Johnson & Johnson) · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies in Lymphoma, Mantle-Cell by Johnson & Johnson — none open to participants now, 1 under way, 1 of them phase 3. Lymphoma, Mantle-Cell · Johnson & Johnson.
Among the 16 studies in Lymphoma, Mantle-Cell by Johnson & Johnson, this one is the only one that started in 2017, is one of 3 observational ones, and was the 12th registered.
1,223 studies on the registry are indexed under Lymphoma, Mantle-Cell; 156 are open to participants now.
Browse Lymphoma, Mantle-Cell studies →None of the 16 studies in Lymphoma, Mantle-Cell by Johnson & Johnson is open now. The open studies under Lymphoma, Mantle-Cell, anywhere →
Of the 125 Lymphoma, Mantle-Cell studies recruiting now, 93 (74%) set no upper age limit and 12 (10%) stop at 75 or younger; 15 take children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 1 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 54 is below the median of 100 across 78 observational studies indexed under Lymphoma, Mantle-Cell.
Median enrollment 48 across the 12 interventional studies, 54 across the 3 observational. Of the 13 that completed or were terminated, 5 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Xian-Janssen Pharmaceutical Ltd., one of the names counted as Johnson & Johnson. Under that name alone:
Xian-Janssen Pharmaceutical Ltd. is the lead sponsor of 36 studies on the registry; 2 are open to participants now.
1 of the studies in Lymphoma, Mantle-Cell by Johnson & Johnson that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT01804686Phase 3Janssen Research & Development, LLCA Long-term Extension Study of PCI-32765 (Ibrutinib) | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 16 studies in Lymphoma, Mantle-Cell by Johnson & Johnson, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of the study (retrospective and prospective) is to describe participant and disease characteristics and treatment pattern of Bortezomib treated mantle cell lymphoma (MCL) participants in China.
Study include mantle cell lymphoma (MCL) participants who were or will be treated by Bortezomib (BTZ) per routine clinical care in multiple tertiary care hospitals after January 1st 2009. Both newly diagnosed MCL participants and relapsed/refractory MCL participants will be included.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants characteristics and treatment pattern of relapsed/refractory mantel cell lymphoma \[rrMCL\]) participants treated by Bortezomib (BTZ) will be observed for cohort 1.
Participants characteristics and treatment pattern of newly diagnosed MCL participants (if more than 20% of total BTZ-treated MCL) will be analysed for cohort 2.
Demographic Characteristic of Participants in Prospective Group: Age
Continuous variable (age) will be summarized using descriptive statistics.
Time frame: Baseline
Participants Disease Status (newly diagnosed MCL or relapsed/refractory mantel cell lymphoma [rrMCL]) Treated With BTZ
Categorical variable (disease status) will be summarized using a frequency distribution with the number and percentage of participants in each category. Treatment response will be analyzed by this variable if newly diagnosed MCL patients account for more than 20 percent (%) of total.
Time frame: Baseline
Eastern Cooperative Oncology Group (ECOG) Performance Status
A worsening in Eastern Cooperative Oncology Group (ECOG) performance status score was defined as greater than or equal to 1-point increase from Baseline. ECOG is a 5-point scale 0=Fully active, 1=Ambulatory, carry out work of sedentary nature, 2=Ambulatory, capable of all self-care, 3=Capable of limited self-care, confined to bed or chair more than 50% of waking hours, 4=Completely disabled, no self-care, totally confined to bed or chair, 5=Dead.
Time frame: Baseline
Ann Arbor Stage
Ann Arbor stage can be obtained from imaging results or directly from admission records. Ann Arbor stage describes areas of involvement; Stage I(IE) - One lymph node region or extralymphatic site (IE); Stage II(IIE)- Two or more lymph node regions or at least one lymph node region plus a single localized extralymphatic site (IIE) on the same side of the diaphragm; stage III (IIIE, IIIS)-Lymph node regions or lymphoid structures (example, thymus,Waldeyer's ring) on both sides of the diaphragm with optional localised extranodal site (IIIE) or spleen (IIIS); stage IV-Diffuse or disseminated extralymphatic organ involvement.
Time frame: Up to Follow-up (approximately 22 months)
Prognostic Index Score
Prognostic index will be summarized using descriptive statistics. For each prognostic factor, 0-3 points are given to each patient and points are summed up to a maximum of 11. Participants with 0-3 points are classified as low risk (44% of participants, median overall survival \[OS\] not reached). Participants with 4-5 points are classified as intermediate risk (35%, median OS 51 months), and patients with 6-11 points as high risk (21%, median OS 29 months).
Time frame: Baseline
Demographic Characteristic of Participants in Prospective Group: Gender
Categorical variable (gender) will be summarized using a frequency distribution with the number and percentage of participants in each category.
Time frame: Baseline
Treatment pattern of BTZ-treated MCL participants: Route of Administration
Primary MCL therapy with Velcade (BTZ) prior MCL treatment, combined MCL treatment and subsequent MCL treatment to extract the information on route of administration (subcutaneous \[SC\] or intravenous \[IV\]) to see if there's any outstanding factor that impacts BTZ's dose/frequency and identify the most popular usage of BTZ.
Time frame: Up to Follow-up (approximately 22 months)
Treatment Pattern of Bortezomib (BTZ) Treated MCL participants: Dose
The cumulated dose will be summarized using descriptive statistics.
Time frame: Up to Follow-up (approximately 22 months)
Treatment Pattern of Bortezomib (BTZ) Treated MCL Participants: Frequency
The frequency of BTZ will be summarized using a frequency distribution with the number and percentage of participants in each category.
Time frame: Up to Follow-up (approximately 22 months)
Treatment Pattern of Bortezomib (BTZ) Treated MCL Participants: Reason of BTZ Initiation/Discontinuation/Dose Adjustment
The reason of BTZ initiation/discontinuation/dose adjustment will be described with respective number of occurrence.
Time frame: Up to Follow-up (approximately 22 months)
Overall Response Rate (ORR)
ORR is defined as the sum of complete response \[CR\] rate (CR+ unconfirmed complete remission \[CRu\]) + Partial remission \[PR\] rate as per International Working Group (IWG 2007) criteria. These response criteria are based on the reduction in the size of the enlarged lymph node as measured by computerized tomography (CT) scan and the extent of bone marrow involvement that is determined by bone marrow aspirate and biopsy. Complete response \[CR\] defined as disappearance of all evidence of disease; CRu satisfies CR criteria, however any residual lymph node mass greater than (\>)1.5 centimeter (cm) in longest transverse dimension or extranodal site of disease (irrespective of size) must have regressed by more than 75% of the product of the longest perpendicular dimensions compared to the pretreatment baseline. PR defined as at least a 50% decrease in sum of the product of the diameters (SPD) of up to six of the largest dominant nodes or nodal masses.
Time frame: Approximately 22 months
Complete Response [CR] Rate (CR+ Unconfirmed Complete Remission CRu)
The percentage of participants with CR and CRu in all participants whose treatment response data are available.
Time frame: Approximately 22 months
Partial Remission (PR) Rate
The percentage of participants with PR in all participants whose treatment response data are available.
Time frame: Approximately 22 months
Time to Response (TTR)
Interval between start of treatment to the first day when CR/CRu or PR was observed.
Time frame: Approximately 22 months
Duration of Response (DOR)
Interval from the date the response was documented to the first day that Progressive Disease (PD) was observed in participants with CR/CRu or PR. PD defined as any new lesions or increase by greater than or equal to (\>=) 50% of previously involved sites from nadir.
Time frame: Approximately 22 months
Progressive-Free Survival (PFS)
Interval between start of treatment to first day when death or PD was observed. PD defined as any new lesions or increase by \>= 50% of previously involved sites from nadir.
Time frame: Approximately 22 months
Overall survival (OS)
Interval from the day of the start of the treatment to death, or the last date when the participant was identified to be alive whichever is late.
Time frame: Approximately 22 months
Ran from Apr 2017 to primary completion in Sep 2019, 29 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Xian-Janssen Pharmaceutical Ltd. →